Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply
Aliment Pharmacol Ther
.
2017 Oct;46(8):770-771.
doi: 10.1111/apt.14282.
Authors
A A Shaheen
1
,
M Al-Mattooq
1
,
S Yazdanfar
1
,
K W Burak
1
,
M G Swain
1
,
S E Congly
1
,
M A Borman
1
,
S S Lee
1
,
R P Myers
1
,
C S Coffin
1
Affiliation
1
Calgary Liver Unit, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
PMID:
28901569
DOI:
10.1111/apt.14282
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenine
Hepatitis B e Antigens
Hepatitis B, Chronic*
Humans
Lipids
Organophosphonates
Tenofovir*
Substances
Hepatitis B e Antigens
Lipids
Organophosphonates
Tenofovir
Adenine